CD14 and fibrosis: Our study, comprising 226 patients with chronic liver diseases (CLD) at various stages of fibrosis/cirrhosis from different disease etiologies and 184 controls, demonstrates that circulating monocytes increase during disease progression, specifically the CD14+CD16+ subset.